Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Nov;19(6):931-933.
doi: 10.1016/j.jcf.2020.05.010. Epub 2020 Jun 6.

Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study

Michelle Shaw  1 , Umer Khan  2 , John P Clancy  3 , Scott H Donaldson  4 , Scott D Sagel  5 , Steven M Rowe  6 , Felix Ratjen  7 ; PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
Affiliations
Free PMC article
Observational Study

Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study

Michelle Shaw et al. J Cyst Fibros. 2020 Nov.
Free PMC article

Abstract

The PROSPECT study, a post-approval observational study in the U.S., showed no significant changes in lung function as measured by spirometry with clinical initiation of lumacaftor/ivacaftor. A sub-study within the PROSPECT study assessed the lung clearance index (LCI), as measured by multiple breath washout (MBW), a measure of lung function demonstrated to be sensitive among people with normal spirometry. Participants performed MBW prior to clinically initiating lumacaftor/ivacaftor therapy and for one year of follow-up. Similar to the whole PROSPECT study, this sub-study cohort (N = 49) had no significant absolute or relative changes in FEV1% predicted at any time point. LCI, however, decreased (improved) by 0.81 units or 5.3% (95% CI -9.7, -0.9%) at 1 month, 0.77 units or 5.9% at 3 months, 0.67 units or 5.9% at 6 months, and 0.55 units or 4.3% at 12 months. These results demonstrate the utility of the LCI in assessing treatment effects of relatively modest size in a heterogenous study population.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest MS has nothing to disclose. UK reports grants from Cystic Fibrosis Foundation, during the conduct of the study and outside the submitted work. JPC reports grants from Cystic Fibrosis Foundation, during the conduct of the study. SHD reports grants from Cystic Fibrosis Foundation, during the conduct of the study. SDS reports a grant from the Cystic Fibrosis Foundation that funds the work under consideration, and grants from the Cystic Fibrosis Foundation and National Institutes of Health funding activities outside the submitted work. SMR reports grants, contracts, and consulting services from Vertex Pharmaceuticals related to the conduct of clinical trials. FR reports grants and personal fees from Vertex, personal fees from Novartis, personal fees from Bayer, personal fees from Roche, personal fees from Genetech, outside the submitted work.

Figures

Fig. 1.
Fig. 1.
Change in lung function measurements throughout the study. Error bars represent 95% confidence intervals around the mean values at each time point.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014. doi:10.1016/S2213-2600(14)70132-8. - DOI - PubMed
    1. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med 2015. doi:10.1056/NEJMoa1409547. - DOI - PubMed
    1. Hubert D, Chiron R, Camara B, et al. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros 2017. doi:10.1016/j.jcf.2017.03.003. - DOI - PubMed
    1. Burgel PR, Munck A, Durieu I, et al. Real-life safety and effectiveness of lumacaftor–ivacaftor in patients with cystic fibrosis. Am J Respir Crit Care Med 2020. doi:10.1164/rccm.201906-1227OC. - DOI - PubMed
    1. Sagel SD, Khan U, Heltsche SL, et al. Clinical effectiveness of lumacaftor/ivacaftor in cystic fibrosis patients homozygous for F508del-CFTR. Ann Am Thorac Soc 2020. Pending. - PMC - PubMed

Publication types